Companies are developing a protein-based vaccine.
Feb 22, 2021 at 2:01 pm TASR
PARIS. Pharmaceutical companies Sanofi and GlaxoSmithKline announced on Monday the start of a new second phase of studies of their vaccine against COVID-19, the DPA agency reported.
The study will evaluate the safety of the vaccine and its ability to elicit a desired or unwanted immune response and to help select the appropriate dose of antibody to use in the third phase of the tests, according to the French company Sanofi on its website. Together with the British concern GSK, it is developing a recombinant protein-based vaccine.
A new phase of studies will allow these companies to find the final formulation of the vaccine for the adult population of all ages. The study will involve 720 volunteers over the age of 18 in Honduras, Panama and the USA. Testing includes the same numbers of people in the group from 18 to 59 years of age and people older than 60 years.
The results of a previous phase of studies last December showed that the immune response of the vaccine in participants aged 18-49 years was comparable to people who had already recovered from covid. However, in older people, this response was lower.
If the second phase is successful, the third phase could start in the second quarter of 2021, according to Sanofi and GSK. The vaccine should be available in the last quarter of this year.
#Sanofi #GlaxoSmithKline #launched #phase #vaccine #study